Safety, tolerability, and pharmacokinetics of intravenous oseltamivir: Single- and multiple-dose phase I studies with healthy volunteers

22Citations
Citations of this article
21Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

There is an unmet need for an intravenous (i.v.) neuraminidase inhibitor, particularly for patients with severe influenza who cannot take oral medication. Two phase I pharmacokinetic and safety studies of i.v. oseltamivir were carried out in healthy volunteers. The first was an open-label, randomized, four-period, two-sequence, single-dose trial of 100 mg, 200 mg, and 400 mg oseltamivir i.v. over 2 h and a 75-mg oral dose of oseltamivir. The second was a double-blind, placebo-controlled, parallel-group, multiple-dose study in which participants were randomized to 100 mg or 200 mg oseltamivir or placebo (normal saline) i.v. over 2 h every 12 h for 5 days. Exposure to the active metabolite oseltamivir carboxylate (OC) after dosing achieved with 100 mg oseltamivir administered i.v. over 2 h was comparable to that achieved with 75 mg administered orally. Single i.v. doses of oseltamivir up to 400 mg were well tolerated with no new safety signals. Multiple-dose data confirmed good tolerability of 100 mg and 200 mg oseltamivir and showed efficacious OC exposures with 100 mg i.v. over 2 h twice daily for 5 days. These results support further exploration of i.v. oseltamivir as an influenza treatment option for patients unable to take oral medication. Copyright © 2012, American Society for Microbiology. All Rights Reserved.

References Powered by Scopus

Clinical aspects of pandemic 2009 influenza a (H1N1) virus infection

968Citations
N/AReaders
Get full text

Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: A randomized controlled trial

968Citations
N/AReaders
Get full text

Pandemic 2009 influenza A(H1N1) virus illness among pregnant women in the United States

825Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Influenza virus resistance to neuraminidase inhibitors

295Citations
N/AReaders
Get full text

Prolonged Influenza Virus Shedding and Emergence of Antiviral Resistance in Immunocompromised Patients and Ferrets

94Citations
N/AReaders
Get full text

Influenza virus resistance to antiviral therapy

73Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Brennan, B. J., Davies, B., Cirrincione-Dall, G., Morcos, P. N., Beryozkina, A., Chappey, C., … Rayner, C. R. (2012). Safety, tolerability, and pharmacokinetics of intravenous oseltamivir: Single- and multiple-dose phase I studies with healthy volunteers. Antimicrobial Agents and Chemotherapy, 56(9), 4729–4737. https://doi.org/10.1128/AAC.00200-12

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 4

40%

Researcher 4

40%

Lecturer / Post doc 2

20%

Readers' Discipline

Tooltip

Medicine and Dentistry 5

36%

Agricultural and Biological Sciences 4

29%

Immunology and Microbiology 3

21%

Pharmacology, Toxicology and Pharmaceut... 2

14%

Save time finding and organizing research with Mendeley

Sign up for free